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To investigate the impact of provider payment reforms and associated care delivery models
on cost and quality in cancer care.
Methods
Data sources/study setting: Review of English-language literature published in PubMed,
Embase and Cochrane library (2007–2019).
Study design: We performed a systematic literature review (SLR) to identify the impact
of cancer care reforms. Primary endpoints were resource use, cost, quality of care, and clini-
cal outcomes.
Data collection/extraction methods: For each study, we extracted and categorized
comparative data on the impact of policy reforms. Given the heterogeneity in patients,
interventions and outcome measures, we did a qualitative synthesis rather than a meta-
analysis.
Results
Of the 26 included studies, seven evaluations were in fact qualified as quasi experimental
designs in retrospect. Alternative payment models were significantly associated with reduc-
tion in resource use and cost in cancer care. Across the seventeen studies reporting data on
the implicit payment reforms through care coordination, the adoption of clinical pathways
was found effective in reduction of unnecessary use of low value services and associated
costs. The estimates of all measures in ACO models varied considerably across participat-
ing providers, and our review found a rather mixed impact on cancer care outcomes.
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Conclusion
The findings suggest promising improvement in resource utilization and cost control after
transition to prospective payment models, but, further primary research is needed to apply
robust measures of performance and quality to better ensure that providers are delivering
high-value care to their patients, while reducing the cost of care.
Introduction
Cancer care is moving toward more advanced, targeted treatments that have the potential to
improve health outcomes. Despite the substantial progress in economic evaluations of medical
interventions, policy makers are increasingly challenged to control rapidly rising healthcare
costs. Available projections for cancer care cost in the United Kingdom, the United States
(US), and Australia suggest a dramatic increase from 42% to 66% above their current levels by
2025 [1], [2],[3]. During the past five years, 68 high-cost, novel therapies were launched glob-
ally for the treatment of cancer [4], so now the challenge is developing more compelling evi-
dence on whether this expensive paradigm shift leads to better outcomes. Additional increases
in cancer treatment costs are associated with the availability of these high-cost novel agents, as
well as use of combination therapies and multiple lines of treatment [4]. As treatment options
increase, further efforts are required to ensure that providers apply efficient resource-utiliza-
tion strategies without adversely affecting the quality of care.
Multiple policy reforms have been launched in cancer care, but provider payment models
remain an area of contention among policy makers. Shifting the orientation of the provider
reimbursement system from services to outcomes requires the identification and reward of
high-quality, patient-centered care [5–9]. This transition is tied to care coordination and ser-
vice delivery models to establish the components of a value-based system. Therefore, a whole-
sale change in practice is expected to take place while adapting performance metrics, operation
systems, and legislative structures to provide value to patients [6, 9–11].
Although the interaction between payers and providers suggests a move from a volume-
based to value-based model in oncology practice, there is still limited evidence on successful
payment reforms. We conducted a systematic literature review (SLR) to identify and summa-
rize existing evidence on the impact of provider payment reforms and care delivery models on
cost and quality measures in cancer care. Previously published literature reviews on this topic
were conducted on the basis of existing narrative reviews, expert opinions, and evaluation
research studies [12–14]. However, this is the first SLR that focuses on methodological studies
reporting comparative data on cost, quality, and clinical outcomes to first describe the land-
scape of policy reforms targeting inefficiency of care, and second to fill the existing knowledge
gap on the effectiveness of such experiments in providing value to patients diagnosed with
cancer.
Materials and method
Data sources and searches
The SLR was conducted in accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines to identify English-language articles pub-
lished between January 1, 2007, and January 15, 2019, reporting the impact of provider pay-
ment reforms and care delivery models in cancer care. Searches were conducted in PubMed,
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Embase, and the Cochrane Library; S1, S2 and S3 Tables present the search algorithms for
each database. This search was supplemented by manual bibliography searches of the identi-
fied studies and authors.
Study selection and data extraction
As show in the Patients, Interventions, Comparators, Outcomes, Time and Study design
(PICOT) selection criteria table (Table 1). primary endpoints were healthcare resource use,
quality, cost, and clinical outcomes. Eligible studies were required to report the impact of pol-
icy reforms comparatively in any cancer care setting. The impact was defined as consequences
of identified interventions on any of these outcome measures. Interventions related to care
delivery models were eligible if they were linked to the provider payments either directly or
implicitly. Case reports of policy reforms were eligible if research methodology was clarified
and met the inclusion criteria. Commentaries, editorials, narrative reviews, and genetic stud-
ies, as well as those with no separable outcomes for cancer care were excluded. Two rounds of
screening took place to identify the relevant literature. In the first round, each title/abstract
was reviewed by one reviewer for inclusion using the PICOT criteria. A 10% random sample
of the articles rejected during this phase were validated by a second reviewer. In the second
round of screening, the full texts of the articles identified during the first pass were reviewed
and validated (see the flow of literature presented in the PRISMA diagram in Fig 1).
Results
The database and hand-searches yielded 4,513 articles, 26 of which were included in the SLR.
Fig 2 presents the network of evidence identified in the literature, providing a clear picture of
Table 1. PICOT inclusion and exclusion criteria for study selection in the SLR.
Criteria Inclusion criteria Exclusion Criteria
Population • Patients diagnosed with cancer
• Physicians providing cancer care either in the outpatient or inpatient
setting
• Payers involved in cancer care reimbursement
Publications that do not evaluate cancer care.
Intervention
Comparator
Explicit payment reforms directly involving financial incentives: Value-
based payment, bundled payments, shared savings programs, partial or
full capitation, fee-for-service (FFS), global budget, pay-for-performance
(P4P), Medicare Modernization Act, other oncology-specific
reimbursement models
Implicit payment reforms through care coordination: Accountable care
organizations (ACOs), oncology care model (OCM), patient-centred
oncology medical home (PCMH), oncology pathways, Other cancer care
delivery models under the umbrella of payment reforms
Studies that do not report the interventions of interest in cancer care
Local or small-size initiatives associated to the care delivery reforms
including hiring patient navigators or implementing triage phone
policies
Outcomes • Utilization / healthcare resource use: hospitalization, physician visits,
outpatient visits, ICU admissions, Emergency department visits, Specialist
visits, length of stay, chemotherapy medication use, time on treatment
• Direct and indirect costs of care: hospital costs, total costs, medication
costs
• Quality of care, adherence to standard of care
• Clinical outcomes: survival rate, response to treatment and cancer
related mortality
Studies that do not report outcomes of interest for the study
population or outcomes not reported separately for cancer care.
Study design Economic analyses, all epidemiological and observational study designs
including but not limited to prospective or retrospective cohort studies,
cost-of-illness studies, Database/claims data analyses, case reports on
policy reforms
Animal, in vitro, or genetic studies, comments/commentary, news,
editorials, or narrative reviews
Other limits limited to articles with an abstract published in English since January 1,
2007 to Jan 15, 2019
Studies published prior to 2007 or after the final search date in 2019,
or not published in English
https://doi.org/10.1371/journal.pone.0214382.t001
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the models that have been carried out in cancer care. Any studies that were conducted in non-
cancer settings (n = 58) or reported no separable outcomes for cancer care (n = 13) were
excluded from the SLR. Most of the studies were conducted in the US, except for two in South
Korea and one in Taiwan.
The included studies presented limited data on the definition of outcomes used, or similar
outcomes were measured in different ways. Given the observed variation in study populations,
Fig 1. Overview of the systematic literature search: PRISMA flow chart. Using a standardized data extraction form, the mean change and standard deviation
of outcome measures within the intervention and comparator groups were extracted and validated accordingly for additional quality assurance. Studies
published in multiple articles were extracted as one study. A risk-of-bias assessment for included publications was undertaken by independent reviewers using
a checklist developed by the Cochrane Collaboration, the Risk of Bias in Non-Randomized Studies of Interventions (ROBINS-I) tool for non-interventional
studies [15]. The seven domains used in the ROBINS-I tool determine the strength of evidence/risk of bias due to confounders, participant selection,
classification of interventions, deviations from intended interventions, missing data, measurement of outcomes, and selection of the reported results. A three-
point Likert scale was applied to score the bias from low to serious for each of the seven domains; this was later validated by a second reviewer.
https://doi.org/10.1371/journal.pone.0214382.g001
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interventions, and outcome measures, we found it inappropriate to perform a meta-analysis to
estimate the effect size of each identified model. Taking statistical considerations into account,
we used thematic analysis to generate descriptive and explanatory themes as they emerged
from the data. Key themes were organized according to the type of reform. All reimbursement
models directly involving financial incentives to providers were grouped as explicit payment
models. Implicit payment reforms carried out following care-coordination programs, delivery
models, or quality initiatives were categorized as implicit payment models.
Fig 2. Evidence network for the provider payment reforms in cancer care identified in the SLR. Direct line indicates head-to-head comparison of the
interventions as emerged from the data. ACO, accountable care organization; CMS, centers for Medicare and Medicaid services; ECAP, endometrial cancer
alternative payment; FFS, fee-for-service; P4P, pay for performance; OCM, oncology care model; PCMH, patient centered medical home.
https://doi.org/10.1371/journal.pone.0214382.g002
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Using the ROBINS-I tool, we found potential sources of bias in these studies. Of the seven
domains scored, confounding and selection bias were found to be the main drivers of risk of
bias, followed by outcome measurement and reporting the results. This is perhaps due to the
nature of the included studies, with no to very limited control on confounders and outcome
measurements. In total, findings indicated that the outcomes reported were moderately biased
across the studies.
Explicit provider payment methods
The impact of financial incentives to cancer care providers was investigated in the context of
the following models. The findings are summarized in Table 2.
■ Per-diem vs. FFS. A single study examined the transition from fee-for-service (FFS)
reimbursement to a per-diem payment system (PDPS). This study involved patients from
seven hospitals in a PDPS program with FFS-based centers [16]. Compared to the controls in
the FFS setting, per-diem reimbursement significantly reduced length of hospital stays
(p = 0.0001) and total medical costs for PDPS participants. Besides a 2.5% decrease in duration
of care (p<0.0001), costs associated with lab tests, cancer treatment, and analgesic medications
dropped by 6.62%, 4.4%, and 0.59%, respectively (p<0.0001). The average reduction in length
of hospital stays was 3.19 days post implementation of the per-diem model [16].
■ Episode-based payment vs. FFS. The impact of episode-based reimbursement in can-
cer care was investigated in two studies, conducted in Taiwan [17] and the US [18], where sig-
nificant improvements in the five-year cost and quality outcomes were reported compared to
the regular FFS payment. A large cohort of Tai patients with stage 0-III breast cancer
(n = 17940) in the bundled-payment program were matched with controls in an FFS setting;
the results indicated significantly better adherence to quality indicators (p<0.001) and an
improved five-year survival rate (p<0.01) within the bundled-payment system. Although the
cumulative medical payments for the FFS group increased by 20%, the five-year medical pay-
ments of the bundled-payment group remained stable[17]. Similarly, in the US-based health-
care system, direct costs of cancer care in an episode-based program dropped by 34%
compared to the predicted costs in a large FFS-based registry, resulting in a net savings of
$33,361,272 [18]. However, drug costs increased by 179%, with a net rise of $13,459,913 due to
the change in chemotherapy prescriptions. A subset analysis of 50 medical groups with at least
70 participants per episode demonstrated the same cost impacts as the base-case analysis.
When using data from another subgroup of lung cancer survivors, no significant difference
was found in patients’ survival between the two payment groups.
■ Pay-for-Performance (P4P) vs. FFS. A simulation model investigated the impact of a
performance-based payment on specialty oncology services compared to FFS spending [19].
Using historical episodes from Medicare claims for FFS beneficiaries, the Centers for Medicare
and Medicaid (CMS) established a model for prevalent cancers (n = 330,647 oncology epi-
sodes). Assuming a target spending for chemotherapy episodes, an extra performance-based
compensation per episode was paid to physicians in addition to the standard FFS-based pay-
ment in practices with episode costs falling below the target. Changes in the quantity and
intensity of services in response to the P4P reform were measured under one of three scenar-
ios: “no change”, “5% reduction” and “10% reduction” from the initial FFS spending. The
study found a range of -5% to +4% change in total spending under the “10% reduction” and
“no behavior” scenarios, respectively, indicating a substantial drop in total costs after imple-
menting the P4P model [19].
■ Capitated-payment model vs. FFS. We identified a single study reporting the impact
of an oncology group’s transition from FFS arrangement to a partial-capitated model [20]. A
Provider payment reforms in cancer care
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indicated AST among low
risk patients
• No significant change in
AST use among metastatic
patients
(Continued)
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six-month follow-up of Medical Advantage enrollees from a single health plan in the US indi-
cated that there were no significant differences in all-cause hospitalizations between the two
payment cohorts. Although the mean number of chemotherapy-related complications and
ambulance transports were greater post-transition, the subset analysis indicated that the post-
capitated group was sicker than the pre-capitated cohort (according to the Deyo-Charlson
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■ Other explicit payment reforms. Three studies reported the impact of provider pay-
ment reform implemented as part of the Medicare Modernization Act, and determined it was
effective in switching treatment patterns and chemotherapy use [21–23]. According to the
findings, regardless of the practice setting, dropping reimbursement rates significantly reduced
chemotherapy prescriptions per patient at three and six last months of life for patients diag-
nosed with a variety of cancer types (p<0.001)[21]. Similarly, a major reduction (64%) in
reimbursement for androgen suppression therapy (AST) in prostate cancer (n = 72,818) signif-
icantly reduced the odds of receiving non-indicated AST (given without other therapies such
as radical prostatectomy or radiation) in low-risk patients (p<0.001) [22]. In contrast, in a
cohort of lung cancer patients, outpatient chemotherapy prescriptions significantly increased,
with the pattern of switching to high-margin drugs because of the reduction in reimbursement
rates. A 2.4% increase was observed in chemotherapy use less than one month after reducing
payment rates for lung cancer services (p<0.001)[23].In one study, the endometrial cancer
alternative payment (ECAP) model, a value-based healthcare reform initiated based on the
Physician Payment Reform Taskforce (PPRTF) in the Society of Gynecologic Oncology
(SGO), was investigated for sources of potential cost savings while promoting quality of care
[24]. An optimized care model was created using claims data from MarketScan and Medicare
databases. The model focused on the rate of minimally invasive surgery, length of stays, and
emergency department (ED) visits/readmissions to compare mean reimbursement per episode
of surgical care among low-risk, early-stage EC patients (n = 29,935). Outcomes were stratified
by three surgical approaches, from 30 days preoperatively to 60 days postoperatively. The
model derived a cost savings of $903 per patient (2.9% of baseline) in MarketScan, and $1243
(5.9% of baseline) in Medicare, as reflected in the proposed value-based reimbursement
strategy.
Implicit payment reforms targeting delivery of care
Eleven studies in the review reported data on care delivery reforms, including adoption of clin-
ical pathways and participation in patient-centered medical home (PCMH), accountable care
organization (ACO), or oncology care model (OCM) programs. The findings are synthesized
and summarized by type of reform within the following sub-sections and Table 3.
■ Adopting clinical pathways. The adoption of clinical pathways was consistently associ-
ated with reductions in resource use and costs for a variety of cancer types. Pathway-based
treatment of patients with thyroid cancer (n = 361) was significantly effective in reducing
length of hospital stays (p = 0.02) and cost per patient (p<0.001) compared to the controls
with off-pathway treatment [25]. Likewise, adopting a clinical pathway program across 46 can-
cer settings (N = 4,713) was associated with a 75% reduction in hospitalization costs per
patient over three years (p = 0 .004), as well as a 30% drop in cost of supportive care per patient
(p<0.001). Chemotherapy drugs and hospitalization costs were found to be the main drivers
of these trends, corresponding to 68% and 32% of the total savings, respectively [26]. The same
impact was observed for the pathway-based treatment of colon cancer, with a substantial
reduction in total adjuvant treatment costs for non-metastatic disease, and a longer survival
time for metastatic patients, compared to the off-pathway group [27]. Significant reductions
were also found in mean total costs per case (p<0.001), treatment costs per patient per month
(p�0.01), chemotherapy costs (p<0.001), and chemotherapy period (p<0.001) for on- versus
off-pathway treatment [27]. A 35% reduction in outpatient costs was observed for patients
with non-small-cell lung cancer (NSCLC); however, no significant difference was found in
12-month survival of such patients treated in the on-pathway versus off-pathway groups
(p = 0.867)[28]. Regarding the impact on resource use and hospital-based billing, evidence-
Provider payment reforms in cancer care
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Table 3. Summary of the studies reporting data on implicit payment reforms through care coordination in oncology practice.
Author, year Country Cancer care delivery
models;.Intervention vs.
comparator





US Adopting level-I colon cancer
pathways vs. off pathway
treatments
Retrospective cohort study




size.N = 1130 patients
• Total costs per
case












On vs. off pathway treatment
in adjuvant group
• Total costs per case: -35%,
p<0.001
• Treatment costs per patient:
-35%, p�0.01
• Chemotherapy costs: -63%,
p<0.001
• Chemotherapy period: -34%,
p<0.001
• Chemotherapy admissions:
-23%, p = 0.236
• DFS: HR = 4.98 (95% CI, 2.11
to 11.74), P<0 .05
In metastatic patients only OS
was significantly longer: 26.9
vs. 20.1 months,P = 0.03
Konski et al.
(2014)
US Pathway-based vs. off-
pathway hypofractionation
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• Workflow reduction: five
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chemotherapy): -8.7%,
p = 0.255
• Hospitalization days per
patient: -32.8%, p = 0.057
• Total drug costs per patient:
+2.5%, p = 0.587
• Total cost savings compared







pathway treatment of thyroid
cancer
Retrospective cohort study Thyroid cancer.
Sample size.N = 361
• Length of hospital
stays




Length of hospital stays: -0.8
days (p = 0.02)




US Before vs. after adopting level
I clinical pathways for the
treatment of lung cancer
Retrospective cohort study














• Outpatient costs: -35%
• Cost of chemotherapy: -37%
• Non-chemotherapy
medications: -39%
• 12-month OS: +2.2%,
p = 0.867
(Continued)
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Table 3. (Continued)
Author, year Country Cancer care delivery
models;.Intervention vs.
comparator
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15-month from diagnosis:
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• Outpatient visits: -22.2%,
p<0.001
• Inpatient hospitalizations: no
differences, p = NR
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• No significant change was
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Medical home vs. FFS
• Last 30-day costs: -$959
(-6%)
• Last 90-day costs: -$3,346
• Last 180-day costs: -$5,790
Colla et al.
(2013)
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• Total hospital costs
ACO vs. non-ACO hospitals:
• Mortality rate: no significant
difference, p = NR
• Length of stay: no significant
difference, p = NR
• Total inpatient costs: no
significant impact on
prostatectomy (p = 0.07),
nephrectomy (p = 0.07) and
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Herrel et al.
(2016)














• Length of stay
ACO vs. non-ACO hospitals:
• 30-day mortality rate: 3.3%
vs. 3.4%, p = 0.54
• 30-day readmission
rate:12.5% vs. 12.4%, p = 0.69
• Complications rate: 43.6% vs.
43.4%, p = 0.65
Length of stays: 10.1% vs.
10.2%, p = 0.56
(Continued)
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based hypofractionation was found to be effective in reducing five patients per day equivalent
to one to 1.5 daily operating hours in a radiotherapy department [29].
■ PCMH vs. FFS. The impact of the Community Oncology Medical Home program on
cancer care spending was compared with FFS Medicare beneficiaries diagnosed with various
cancer types. After adjustment for clinical and sociodemographic differences, implementing
PCMH model was found to be associated with significantly reduced (10.2%) ED visits per
1,000 patients (p = 0.024), resulting in 8.1% savings relative to average spending per benefi-
ciary over six months [30]. A similar result was observed for Medicare expenditures in the last
year of life for beneficiaries with cancer. The average end-of-life costs in the last 30, 90, and
180 days dropped for patients in a PCMH program compared to the FFS Medicare claims for
similar outpatient oncology practices [31]. Michigan Oncology Medical Home was also effec-
tive in reducing the first-year costs through avoiding unnecessary ED visits and inpatient
admissions across four cancer practices, with an average estimated cost savings of $550 per
patient [32]. However, according to another study, the impact of PCMH enrollment was, in
some measure, associated with increased resource use and cost. A significant increase in
monthly Medicaid expenditures and the number of outpatient visits for PCMH enrollees was
Table 3. (Continued)
Author, year Country Cancer care delivery
models;.Intervention vs.
comparator










• Use of curative
treatment
• Total spending
ACO vs. non-ACO enrollees
• Use of curative treatment: no
significant change, p = 0.33
Spending one-year after
diagnosis: +5.8%, p = 0.03
Lam et al.
(2018)














ACO vs. non-ACO enrollees
post-reform:
• Total spending: no
significant change, p = 0.94
• No significant change in
inpatient (p = 0.31), outpatient
(p = 0.32), physician services
(p = 0.81), and chemotherapy
spending (p = 0.81)
Meyer et al.
(2017)
US ACO vs. non-ACO practices Retrospective cohort study









ACO vs. non-ACO enrollees
• The prevalence of breast
cancer screening: +40%,
p<0.001
















ACO vs. non-ACO hospitals:
• Utilization of cancer
screening/imaging services per
100 beneficiaries: -2.4% (95%
CI: -4.1, -0.7).
• Total spending on low-value
services: -4.5% (p = 0.004).
Mendenhal
et al. (2018)
US Oncology Care Model
(OCM) program
Retrospective cohort study
using data from Chronic
Condition Warehouse
Mix of cancer types
(Not specified).






• Acute care admissions rate:
-16%, p = 0.005
• Net savings in inpatient costs
in the first year: $798,000
https://doi.org/10.1371/journal.pone.0214382.t003
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observed over the first 15 months from diagnosis compared to non-PCMH participants
(p<0.001), with no significant impact on inpatient hospitalizations or ED visits [33].
■ ACO vs. non-ACO (FFS). Compared to the non-ACO participants, Medicare benefi-
ciaries with prostate cancer who were aligned with ACOs (n = 1,100) had similar rates of treat-
ment (p = 0.33), but significantly increased spending in the year after diagnosis [34]. In
another study on patients with urologic cancer who underwent elective major surgery, no sig-
nificant differences were observed in total inpatient costs, length of hospital stays, and mortal-
ity rate among patients within 176 ACO hospitals compared to 352 non-ACO sites [35].
Similarly, the ACO model was found to have no significant association with post-surgery com-
plication rate (p = 0.65), prolonged length of stays (p = 0.56), and readmission rate (p = 0.69)
among patients undergoing major resection surgeries (n = 384,519) in ACO hospitals, com-
pared to the non-ACO enrollees within 2,516 cancer centers [36]. In a larger scope, across 11
different cancer types from five-year national Medicare claims, having a cancer diagnosis in a
Medicare ACO had no significant impact on healthcare spending and resource utilization
[37]. However, in specific medical scenarios, the first year of the Medicare Pioneer ACO pro-
gram was found to be effective in reducing the utilization of low-value services, defined as pro-
viding minimal or no average clinical benefit. Compared to the control group, a reduction of
0.8 services per 100 beneficiaries was observed in the ACO model with 693,218 person-years.
This corresponds to a 4.5% drop in total spending on low-value services (p = 0.004). The great-
est absolute reductions in service utilization post-ACO participation was observed in cancer
screening and imaging tests, the most frequently delivered services [38].
Similarly, in a study by Colla et.al [39],the Physician Group Practice Demonstration
([PGPD] used as a proxy for ACO) was significantly associated with an annual reduction of
3.9% in payments per beneficiary. Major reductions in inpatient service use, hospital discharges,
and intensive care unit (ICU) stays were identified, but no changes in cancer-specific proce-
dures or chemotherapy were observed post-PGPD program. In cancer preventive care, ACO
enrollment was also effective in increasing the utilization of preventive screening tests among
patients with breast or prostate cancer. The prevalence of screening tests for both cancers was
higher among ACO participants compared to non-ACO enrollees (p<0.001) [40]. Although the
screening for prostate cancer was in the ACO model, it was not recommended by the US Pre-
ventive Services Task Force (USPSTF). Thus, delivering high-quality care in ACO models needs
to be linked to the standard of care in order to control unnecessary use of low-value services.
■ OCM. The SLR identified a cancer care delivery reform, implemented as a five-year
model by CMS to provide coordinated, high-quality care for oncology practices using alterna-
tive payment arrangements with CMS; this included financial and clinical performance
accountability for episodes of care. Mendenhall et.al [41] used risk-adjusted national averages
of all practices providing cancer care in the same patient risk quartile as the comparator cohort
to evaluate the impact of a multifaceted care delivery approach targeting unnecessary ED and
hospital admissions. The strategy included increased care coordination, adopting standardized
pathways, urgent care tactics, and patient education. The findings indicated that there was a
statistically significant reduction (16%) in hospital admissions (p = 0.005), resulting in a net
saving of $798,000 in inpatient costs per quarter for 1,600 patients in the first year of the OCM
program. Additionally, quarterly basis surveys demonstrated that OCM patient satisfaction
scores improved over the course of year 1 in the program.
Discussion
Payment reform requires more compelling evidence to ensure providers are delivering high-
value, quality care to their patients, while reducing the cost of such care. An SLR such as this
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can help stakeholders and payers understand the successes and failures of the reforms. Our
review found that alternative payment models demonstrated promising outcomes in reducing
healthcare resource use and costs, although they are still lacking robust measures of perfor-
mance and quality. Of the interventions involving reimbursement reforms either directly or
implicitly through care coordination models, most improved resource utilization and/or cost
of care. Consistent with the previously published literature [42–45], adopting oncology path-
ways significantly reduced chemotherapy duration, hospitalizations, length of stays, and asso-
ciated costs by avoiding unnecessary use of low-value services. The common method used to
determine the effectiveness of pathways was evaluating whether their use resulted in cost sav-
ings relative to off-pathway treatments across all studies. However, this savings could not be
linked to the cost drivers, which vary across cancer types and mainly depend on patient char-
acteristics, disease stage, goals of therapy, available treatment options, and patient preferences.
Although standardization of care appeared to be an effective strategy in targeting expensive
chemotherapy treatments, little information was available regarding the impact of adherence
to guidelines on clinical outcomes, treatment complications, and patient’s quality of life and
satisfaction. It is unlikely to find a randomized trial with off-pathway versus pathway-based
treatment arms; therefore, the strength of retrospective evaluation is in the ability to examine
comprehensive electronic health records and claims data. The impact of adherence to stan-
dards can be more definitively measured as pathways are further adopted and implemented in
cancer care, allowing for assessments of different modalities in a variety of settings in the short
versus long term.
This review also identified notable findings regarding other implicit payment models that
involve care coordination across providers. With the PCMH model, most studies reported
potential savings in costs of care derived from significant drops in ED visits and inpatient
admissions; in contrast, longer follow-up of patients until 15 months post-diagnosis indicated
significant increase in outpatient service use and average expenditures per month. The
increase in outpatient services for breast cancer is likely due to the greater access to care
through PCMH that can result in addressing unmet needs of patients. However, a lack of evi-
dence on time-varying characteristics and risk profiles of patients across PCMH models
requires further research to extend the evaluation time span beyond the initial months post-
diagnosis with more intensive treatment per cancer type.
The estimates of all measures in ACO models varied considerably across participating pro-
viders, and our review found a rather mixed impact on cancer care outcomes. It appears that
improvements in some of the key cancer care domains, including screening, surveillance, and
end-of-life care are more responsive to the ACO model than surgical outcomes in certain set-
tings. Improvement in specialized outcome measures in cancer care may be more difficult to
achieve through the ACO model, as most of the ACO quality metrics are not specifically
focused on the complex care coordination in oncology practice. Additionally, the effects
derived from ACO policies may become stronger over time as organizational changes take
place, and the culture of coordination takes shape. As more data become available, covering
the existing gap in time trends and lack of value-based metrics will be important to better eval-
uate the impact of the ACO model in cancer care.
The findings of this study also suggest promising cost savings from transition to prospective
reimbursement models, in which financial risks and accountability are redistributed towards
providers in cancer care; these results are consistent with such findings in non-cancer settings
[6, 9–11]. Although there is lack of evidence on whether quality of care was compromised in
alternative payment models, resource use improvements were somewhat evident in per-diem
payment, pay for performance, episode-based reimbursement, and Medicare Modernization
Act reforms. Despite this, the effect size of the cost savings seemed to fall short in bending the
Provider payment reforms in cancer care
PLOS ONE | https://doi.org/10.1371/journal.pone.0214382 April 5, 2019 14 / 19
cost curve, due to the absence of more aggressive payment reforms in cancer practice. Under-
standing the multiple factors influencing the impact of value-based purchasing models is cru-
cial to evaluating these types of reform that are tailored to the specific setting and target
population. At a higher level, general healthcare policies and regulations as well as other qual-
ity improvement initiatives are important to the success of alternative payment models. How-
ever, the structure of the healthcare systems, provider characteristics, patient population and
preferences, and their risk profiles are the key components in designing, implementing, and
evaluating payment reforms, for which there was no evidence available according to our find-
ings. In addition, the complexity of quality metrics is important to consider in evaluating the
appropriateness and effectiveness of financial incentives, as providers need to understand the
metrics and link them to the incentives.
Our study should be interpreted in the context of several important limitations. First, there
is possibility of publication bias, as is part of the challenges associated with conducting SLRs.
However, additional resources were identified through hand-searching the reference list of
publications. Second, the possibility of selection bias in patients and policy interventions is
inherent to the design of the included studies. Our careful attention to the quality of the evalu-
ation research from which we captured data allowed for transparency and a full understanding
of the strength of evidence using the ROBINS-I risk-assessment tool. According to our find-
ings provided in Table 4, nearly half of the studies were subject to confounding bias, which
highlights the difficulty of evaluating health policy reforms using observational data. Failure to
evaluate potential confounders across the included studies may have biased our results towards
erroneous conclusions on the impact of payment reforms. This observation warrants future
studies that are at the very least quasi experimental designs with either interrupted time series
or pre-post difference in differences construct. Furthermore, the use of manual or propensity
score matching is essential to mitigate the imbalances due to selection bias.
The nature of variability across the studies, together with clinical, methodological, and sta-
tistical sources of heterogeneity were other barriers to evaluating the impact of reforms. There
was no group of studies sufficiently homogeneous in terms of patients, interventions, or out-
come measures to pool data or perform a meta-analysis to estimate the overall impact of each
model. This likely reflects the developing nature of the policy reforms in the fast-evolving field
of cancer. From a practical point of view, this study provides a tabular summary of all studies
related to each key piece of information identified as important for resource use and quality
improvement in cancer care. The findings from this evidence review should be useful to pol-
icymakers, providers, and payers since it covers an important aspect of cancer care reform.
Conclusion
Of the implicit payment models driving quality improvements in cancer care, provider’s
adherence to oncology pathways was significantly effective in resource use improvement.
Despite this, it was difficult to get a clear picture of the effect that participating in PCMHs has
on cancer care outcomes in the long term due to an insufficient number of evaluations. Much
anticipated, but overdue, is the impact of ACO models with ambitions to capitalize on the cost
savings of better care coordination in management of chronic diseases. However, the evalua-
tions of ACOs in cancer care found mixed results, with Medicare Pioneer ACO demonstrating
some reduction in utilization of certain low-value services in the first year. The findings also
suggest promising improvement in resource utilization and cost control after transition to pro-
spective payment models, but, further primary research is needed to apply robust measures of
performance and quality to better ensure that providers are delivering high-value, quality care
to their patients, while reducing the cost of care.
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interventions







Risk of bias in
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Colla, 2012 Serious Moderate Moderate Low Low Moderate Low Moderate
Colla, 2013 Low Low Moderate Low Low Moderate Low Low
Colligan, 2017 Low Low Moderate Low Low Moderate Low Low
Elliott, 2010 Low Low Moderate Low Low Moderate Low Low
Ems, 2018 Low Low Moderate Low Low Moderate Low Low
Herrel, 2015 Serious Moderate Moderate Low Low Moderate Low Moderate
Herrel, 2016 Low Low Moderate Low Low Moderate Low Low
Hollenbeck,
2017
Serious Moderate Moderate Low Low Moderate Low Moderate
Hoverman,2011 Serious Moderate Moderate Low Low Moderate Low Moderate
Jacobson, 2010 Serious Moderate Moderate Low Low Moderate Low Moderate
Kohler,2015 Serious Low Moderate Low Low Moderate Low Low
Konski,2014 Moderate Moderate Moderate Low Low Moderate Low Moderate
Kreys, 2013 Serious Moderate Moderate Low Low Moderate Low Moderate
Kuntz, 2014 Moderate Moderate Low Low Low Moderate Low Moderate
Kwon, 2018 Serious Moderate Moderate Low Low Moderate Low Moderate
Lam, 2018 Low Low Moderate Low Low Moderate Low Low
Mendenhal,
2018
Moderate Moderate Moderate Low Low Moderate Low Moderate
Meyer, 2017 Low Low Moderate Low Low Moderate Low Low
Neubauer, 2010 Serious Moderate Moderate Low Low Moderate Low Moderate
Newcomer,
2014
Serious Moderate Moderate Low Low Moderate Low Moderate
Schwartz, 2015 Low Low Moderate Low Low Moderate Low Low
Shin, 2017 Serious Moderate Moderate Low Low Moderate Low Moderate
Wang, 2017 Low Low Moderate Low Low Moderate Low Low
Waters, 2019 Low Low Moderate Low Low Moderate Low Low
White, 2015 Moderate Moderate Moderate Low Low Low Low Low
Wright, 2018 Low Low Moderate Low Low Moderate Low Low
https://doi.org/10.1371/journal.pone.0214382.t004
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